Skip to main content

#151890

T47D-182R2 Cell Line

Cat. #151890

T47D-182R2 Cell Line

Cat. #: 151890

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Cancer cell line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne Lykkesfeldt

Institute: Danish Cancer Society

Tool Details
Target Details
Applications
Handling
Related Tools
References
Documentation

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: T47D-182R2 Cell Line
  • Cancer: Breast cancer
  • Cancers detailed: Breast cancer;Fulvestrant resistant
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: T47D/S5
  • Organism: Human
  • Tissue: Breast
  • Donor: Female, Caucasian, 54Y
  • Disease: Cancer
  • Growth properties: Adherent
  • Model: Cancer cell line
  • Description: T47D-182R2 is an adherent human breast cancer cell line that exhibits resistance to fulvestrant (Faslodex). It was developed from the parental T47D/S5 cell line through long-term exposure to 100 nM fulvestrant. The cells retain an epithelial morphology. As resistance to fulvestrant—a common second-line endocrine therapy—is a clinical challenge, T47D-182R2 represents a valuable model for studying acquired resistance mechanisms. It serves as a robust tool for identifying targeted therapies against resistant tumor cells, as well as for evaluating strategies to prevent or delay resistance emergence.
  • Production details: Human breast cancer cell line derived from T47D/S5 by long term treatment with 100 nM fulvestrant.
  • Cellosaurus id: CVCL_1D35

Target Details

  • Target: Oestrogen receptor

Applications

  • Application notes: Estrogen and progesterone receptor negative.

Handling

  • Format: Frozen
  • Passage number: Passage 165 (AL3370, AL3384)
  • Growth medium: Phenol red free RPMI 1640 + 5% FCS + glutamax + 8ug Insulin/ml + 100 nM fulvestrant. Fetal Calf Serum (FCS) typically contains less estrogen than Fetal Bovine Serum (FBS) and is the preferred supplement for this cell line.
  • Temperature: 37°C
  • Atmosphere: 5% CO₂
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage medium: 10% DMSO in FCS
  • Subculture routine: Following thawing and counting, dilute the cell suspension with sufficient medium and distribute 5 mL each into T25 flasks to achieve a seeding density of 1.8 - 2.0 x 10^4 / cm2. Place in 37°C, 5% CO₂ incubator. Change medium after 24 hours to remove residual DMSO and then every 2-3 days. Subculture routine: Split 1:7 weekly (slow growing cell line) with Trypsin-EDTA for detachment at 37 °C for 5 minutes. Please also see detailed protocol within the Product Datasheet in the Documentation section below.

Related Tools

  • Related tools: T47D/S2 Cell Line

References

  • Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
  • Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
  • Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
  • SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
  • Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
  • T47D breast cancer cells switch from ER...

Documentation

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.